BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 31933417)

  • 1. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence.
    Kitsos-Kalyvianakis K; Pitsikakis K; Mamalis ME; Kalampokis E; Tan YS; Thangavelu A; Broadhead T; Nugent D; Dejong D; Laios A
    Anticancer Res; 2024 Jun; 44(6):2645-2652. PubMed ID: 38821579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.
    Sinukumar S; Rajan F; Mehta S; Damodaran D; Zaveri S; Kammar P; Bhatt A
    Eur J Surg Oncol; 2021 Jan; 47(1):75-81. PubMed ID: 30857879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
    How JA; Legarreta AF; Handley KF; Fellman B; Foster KI; Glassman D; Vuttaradhi VK; Brodsky AL; Lawson B; Frumovitz M; Westin SN; Ramondetta LM; Gershenson DM; Sood AK; Hillman RT
    Am J Obstet Gynecol; 2024 May; 230(5):544.e1-544.e13. PubMed ID: 38191019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
    Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection.
    Sanson C; Roosen A; Faron M; Zaccarini F; Maulard A; Scherier S; Pautier P; Leary A; Chargari C; Espenel S; Genestie C; Morice P; Gouy S
    Int J Gynecol Cancer; 2024 May; 34(5):730-737. PubMed ID: 38485223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer.
    Chen Y; Sun Z; Cai S; Hu Y; Jiang R; Xiang L; Zang R
    J Gynecol Oncol; 2024 May; 35(3):e25. PubMed ID: 38130134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study.
    Chen T; Xu J; Xia B; Wang H; Shen Y
    J Gynecol Oncol; 2024 Jan; 35(1):e22. PubMed ID: 37945326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.
    Zhao M; Gao Y; Yang J; He H; Su M; Wan S; Feng X; Wang H; Cai H
    Eur J Med Res; 2024 Mar; 29(1):179. PubMed ID: 38494480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involved-field radiation therapy for locoregionally recurrent ovarian cancer.
    Brown AP; Jhingran A; Klopp AH; Schmeler KM; Ramirez PT; Eifel PJ
    Gynecol Oncol; 2013 Aug; 130(2):300-5. PubMed ID: 23648467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery for Recurrent Epithelial Ovarian Cancer.
    Fotopoulou C; Eriksson AG; Yagel I; Chang SJ; Lim MC
    Curr Oncol Rep; 2024 Jan; 26(1):46-54. PubMed ID: 38091202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the quantitative characteristics of dual-energy spectral CT and cytoreduction surgery outcome in patients with advanced epithelial ovarian cancers: A prospective observational study.
    Xu X; Chen Y; Zhang X; Wang Y
    Medicine (Baltimore); 2024 Mar; 103(10):e37437. PubMed ID: 38457565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidisciplinary Surgical Approach to Increase Survival for Advanced Ovarian Cancer in a Tertiary Gynaecological Oncology Centre.
    Mulligan K; Corry E; Donohoe F; Glennon K; Vermeulen C; Reid-Schachter G; Thompson C; Walsh T; Shields C; McCormack O; Conneely J; Khan MF; Boyd WD; McVey R; O'Brien D; Treacy A; Mulsow J; Brennan DJ
    Ann Surg Oncol; 2024 Jan; 31(1):460-472. PubMed ID: 37875740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis.
    Yang SL; Si LH; Lin RX; Gu SY; Li JH; Cui JZ; Yan CH; Farah AM; Jia Y
    Curr Probl Cancer; 2023 Dec; 47(6):101014. PubMed ID: 37718231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial to compare short-term outcomes following infragastric and infracolic omentectomy at the time of primary debulking surgery for epithelial ovarian cancer with normal-appearing omentum.
    Dong X; Yuan L; Zou R; Yao L
    J Ovarian Res; 2024 Apr; 17(1):85. PubMed ID: 38641834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study.
    Prost P; Duraes M; Georgescu V; Rebel L; Mercier G; Rathat G
    Ann Surg Oncol; 2024 May; 31(5):3269-3279. PubMed ID: 38393461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First external validity study of the Fagotti score in ovarian cancer.
    Sarah A; Mathieu L; Henri A; Marcos B; Geoffroy C; Pauline C; Tristan G; Cyrille H; Yohan K; Martin K; Lise L; Lobna O; Émilie R; Vincent L; Guillaume L
    Sci Rep; 2024 May; 14(1):12133. PubMed ID: 38802436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy.
    Chase D; Perhanidis J; Gupta D; Kalilani L; Golembesky A; González-Martín A
    JCO Clin Cancer Inform; 2023 Jun; 7():e2200189. PubMed ID: 37294913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
    Cabasag CJ; Butler J; Arnold M; Rutherford M; Bardot A; Ferlay J; Morgan E; Møller B; Gavin A; Norell CH; Harrison S; Saint-Jacques N; Eden M; Rous B; Nordin A; Hanna L; Kwon J; Cohen PA; Altman AD; Shack L; Kozie S; Engholm G; De P; Sykes P; Porter G; Ferguson S; Walsh P; Trevithick R; Tervonen H; O'Connell D; Bray F; Soerjomataram I
    Gynecol Oncol; 2020 Apr; 157(1):234-244. PubMed ID: 32005583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.